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Summary
Clinical characteristics
Progressive myoclonic epilepsy type 1(EPM1) is a neurodegenerative disorder characterized by onset from age 
six to 15 years, stimulus-sensitive myoclonus, and tonic-clonic epileptic seizures. Some years after the onset, 
ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are cognitively mostly 
within the normal range, but show emotional lability and depression. The epileptic seizures are usually well 
controlled by antiseizure medications, but the myoclonic jerks are progressive, action activated, and treatment 
resistant, and can be severely disabling.
Diagnosis/testing
The diagnosis of EPM1 is established in a proband with suggestive findings and either biallelic abnormal CCC-
CGC-CCC-GCG dodecamer repeat expansions in CSTB or compound heterozygosity for a CSTB dodecamer 
repeat expansion and a CSTB sequence variant (i.e., single-nucleotide variant or indel) identified by molecular 
genetic testing.
Management
Treatment of manifestations: Symptomatic pharmacologic and rehabilitative management, including 
psychosocial support, are the mainstay of care; valproic acid, the first drug of choice, diminishes myoclonus and 
the frequency of generalized seizures; clonazepam, approved by FDA for the treatment of myoclonic seizures, is 
an add-on therapy; high-dose piracetam is used to treat myoclonus; levetiracetam, brivaracetam, and 
perampanel appear to be effective for both myoclonus and generalized seizures. Topiramate and zonisamide may 
also be used as add-on therapy.
Surveillance: Lifelong clinical follow up including evaluation of drug treatment and rehabilitation.
Author Affiliations: 1 Folkhälsan Research Center and University of Helsinki, Helsinki, Finland; Email: anna-
elina.lehesjoki@helsinki.fi. 2 Kuopio Epilepsy Center, Kuopio University Hospital, Member, EpiCARE ERN, University of 
Eastern Finland, Kuopio, Finland; Email: reetta.kalviainen@kuh.fi.
Copyright © 1993-2021, University of Washington, Seattle. GeneReviews is a registered trademark of the University of 
Washington, Seattle. All rights reserved.
Agents/circumstances to avoid: Phenytoin aggravates neurologic symptoms or even accelerates cerebellar 
degeneration; sodium channel blockers (carbamazepine, oxcarbazepine), GABAergic drugs (tiagabine, 
vigabatrin), and gabapentin and pregabalin may aggravate myoclonus and myoclonic seizures.
Genetic counseling
EPM1 is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% 
chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected 
and not a carrier. Once both CSTB pathogenic variants in a family are known, carrier testing for at-risk relatives, 
prenatal testing for pregnancies at increased risk, and preimplantation genetic testing are possible.
Diagnosis
Suggestive Findings
The diagnosis of progressive myoclonic epilepsy type 1 (EPM1) is suspected in a previously healthy child age six 
to 15 years who manifests the following:
• Involuntary, action-activated myoclonic jerks AND/OR generalized tonic-clonic seizures
• Photosensitive, generalized spike-and-wave and polyspike-and-wave paroxysms on EEG
• Abnormal EEG (always abnormal, even before the onset of manifestations). The background activity is 
labile and may be slower than normal. Photosensitivity is marked.
• A gradual worsening of the neurologic manifestations (myoclonus and ataxia), difficulties running, 
playing sports, using stairs
• Normal brain MRI
Establishing the Diagnosis
The diagnosis of EPM1 disease is established in a proband with suggestive findings and either biallelic abnormal 
CCC-CGC-CCC-GCG dodecamer repeat expansions in CSTB or compound heterozygosity for a CSTB 
dodecamer repeat expansion and a CSTB sequence variant (i.e., single-nucleotide variant or indel) identified by 
molecular genetic testing (see Table 1).
Note: Pathogenic dodecamer repeat expansions in CSTB cannot be detected by sequence-based multigene 
panels, exome sequencing, or genome sequencing.
Repeat sizes
• Normal. 2 to 3 dodecamer repeats
• Uncertain significance. 12-17 dodecamer repeats (unstable, but not clinically characterized)
• Pathogenic (full penetrance). ≥30 dodecamer repeats
Note: The dodecamer repeat sequence is CCC-CGC-CCC-GCG. Repeats of 4-11 and 18-29 have not been 
observed.
Molecular genetic testing relies on targeted analysis to characterize the number of CSTB CCC-CGC-CCC-GCG 
dodecamer repeats (see Table 7).
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Table 1. Molecular Genetic Testing Used in Progressive Myoclonic Epilepsy Type 1
Gene 1 Method 2, 3 Proportion of Probands with a Pathogenic Variant Detectable by Method
CSTB
Targeted analysis for the dodecamer 
expansion ~90% 
4, 5
Sequence analysis 6 ~10% 4
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Table 7 for specific methods to characterize the number of dodecamer (CCC-CGC-CCC-GCG) repeats in CSTB.
3. Sequence-based multigene panels, exome sequencing, and genome sequencing cannot detect pathogenic repeat expansions in this 
gene.
4. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants 
may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene 
deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
5. Lalioti et al [1997], Joensuu et al [2008]
6. ~99% in Finnish individuals [Joensuu et al 2008]
Clinical Characteristics
Clinical Description
In more than half of individuals with progressive myoclonic epilepsy type 1 (EPM1) the first manifestation is 
involuntary myoclonic jerks [Kälviäinen et al 2008, Hyppönen et al 2015]. The myoclonic jerks are action 
activated and stimulus sensitive and may be provoked by light, physical exertion, and stress. They occur 
predominantly in the proximal muscles of the extremities and are asynchronous; they may be focal or multifocal 
and may generalize to a series of myoclonic seizures or even status myoclonicus (continuous myoclonic jerks 
involving a semi-loss of consciousness).
During the first five to ten years, the symptoms/myoclonic jerks characteristically progress and about one third 
of affected individuals become severely incapacitated (wheelchair bound). Although the myoclonic jerks are 
disabling and resistant to therapy, the individual usually learns to tolerate them over time, if psychosocial 
support is good and depression not too severe.
In almost half of individuals, the first manifestation is tonic-clonic seizures. There may also be absence, 
psychomotor, and/or focal motor seizures. Epileptic seizures, infrequent in the early stages of the disease, often 
increase in frequency during the ensuing three to seven years. Later they may cease entirely with appropriate 
antiepileptic drug treatment. In rare cases, tonic-clonic seizures do not occur.
Neurologic findings initially appear normal; however, experienced observers usually note recurrent, almost 
imperceptible myoclonus, especially in response to photic stimuli or other stimuli (threat, clapping of hands, 
nose tapping, reflexes) or to action (movements made during neurologic examination) or to cognitive stimuli 
(task demanding cognitive and psychomotor processing). Some years after the onset, ataxia, incoordination, 
intentional tremor, and dysarthria develop.
Cognitive performance, especially memory, is mostly within the normal range. However, affected individuals 
may exhibit poor performance in time-limited tests dependent on motor functions.
The disease course is inevitably progressive; however, the rate of deterioration – especially in terms of walking 
capacity – appears to vary even within the same family. Generalized tonic-clonic seizures are usually controlled 
with treatment, but myoclonic jerks may become severe, appear in series, and inhibit normal activities 
[Magaudda et al 2006, Hyppönen et al 2015]. Myoclonic jerks may also be subcortical in origin and therefore 
difficult to control [Danner et al 2009]. The individual becomes depressed and progression ensues. Education is 
often interrupted because of emotional, social, and intellectual problems.
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In the past, life span was shortened; many individuals died eight to 15 years after the onset of disease, usually 
before age 30 years. With better pharmacologic, physiotherapeutic, and psychosocial supportive treatment, life 
expectancy is comparable to controls up to age 40 years, but is poorer over the long term. Death occurs mainly 
due to respiratory infections [R Kälviäinen, personal communication].
Genotype-Phenotype Correlations
Individuals with pathogenic variants in CSTB usually develop similar disease manifestations. There is evidence 
that correlation exists between the length of the expanded dodecamer repeat and the age of onset or disease 
severity [Hyppönen et al 2015]. However, disease severity also varies among affected individuals within a family 
with apparently similar repeat-size expansions.
Moreover, EPM1 resulting from compound heterozygosity for a dodecamer repeat expansion and a sequence 
variant (i.e., single-nucleotide variant or indel) often presents with earlier age of onset, more severe myoclonus, 
and seizures that may be drug resistant [Koskenkorva et al 2011, Canafoglia et al 2012]. It has been also 
suggested that compound heterozygosity causes a more severe EPM1 phenotype in affected males than females, 
but the numbers are small [Assenza et al 2017].
Recently, homozygous stop-codon and frameshift pathogenic variants in CSTB were associated with infantile-
onset progressive disorders with unexplained severe developmental delay, microcephaly, and hypomyelination 
[Mancini et al 2016, O'Brien et al 2017).
Nomenclature
Progressive myoclonic epilepsy type 1 (EPM1) was originally referred to as Baltic myoclonus (or Baltic 
myoclonic epilepsy) and Mediterranean myoclonus. EPM1 is known to occur worldwide, and thus these 
toponyms are misleading and should no longer be used.
Prevalence
EPM1 has the highest incidence among the progressive myoclonic epilepsies (PMEs), a term that includes a large 
and varied group of diseases characterized by stimulus-sensitive myoclonus, epilepsy, and progressive neurologic 
deterioration.
EPM1 occurs worldwide. Prevalence is increased in certain populations:
• The North African countries of Tunisia, Algeria, and Morocco, where exact prevalence figures are not 
available
• Finland, where its prevalence (2:100,000) is higher than anywhere else in the world [R Kälviäinen, 
personal communication]. The incidence in Finland is estimated at 1:20,000 births.
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with germline 
pathogenic variants in CSTB.
Differential Diagnosis
At the onset of progressive myoclonic epilepsy type 1 (EPM1), juvenile myoclonic epilepsy (JME) (OMIM 
PS254770) – which has a more favorable outcome – should be considered as a diagnostic alternative. Individuals 
with JME have a normal neurologic examination and undisturbed background of the EEG.
Other disorders to consider in the differential diagnosis of EPM1 are summarized in Table 2.
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Table 2. Genes of Interest in the Differential Diagnosis of Progressive Myoclonic Epilepsy Type 1
Gene(s) Disorder MOI
Clinical Characteristics of Differential Diagnosis Disorder
Overlapping w/EPM1 Distinguishing from EPM1
EPM2A
NHLRC1 PME, Lafora type AR
• PME
• Focal occipital seizures & fragmentary, 
symmetric, or generalized myoclonus 
beginning in previously healthy 
individuals
• Later onset (age 8-19 yrs); rapid 
disease progression; death ~10 yrs 
after diagnosis
• Prior to the availability of 
molecular genetic testing, 
histologic findings on skin biopsy 
established the diagnosis.
GOSR2 EPM6 (OMIM 614018) AR
• Early-onset ataxia (average age 2 yrs) 
followed by action myoclonus & 
seizures later in childhood
• Independent ambulation lost in 2nd 
decade
Earlier onset; scoliosis (develops by 
adolescence)
KCNC1 EPM7 (OMIM 616187) AD
• Resembles EPM1 at disease onset 1
• Presents at age 6-15 yrs w/myoclonus 
(sometimes reported as tremor)
• The later disease course is 
characterized by moderate-to-severe 
incapacitating myoclonus, infrequent 
tonic-clonic seizures, ataxia, & mild (if 
any) cognitive decline.
EPM7 & EPM1 have a remarkably similar 
clinical presentation. EPM7 may have a 
somewhat more severe progression than 








• Onset usually in childhood, after 
normal early development
• Brain MRI often shows brain 
atrophy & basal ganglia 
calcification.
• Muscle biopsy typically shows 
RRF.
SCARB2 Action myoclonus - renal failure syndrome AR
Typically presents at ages 15-25 yrs; may 
present w/neurologic symptoms (e.g., tremor, 
action myoclonus, seizures, ataxia) 2
May present w/proteinuria that progresses 
to renal failure
AD = autosomal dominant; AR = autosomal recessive; Mat = maternal; MERRF = myoclonic epilepsy with ragged red fibers; MOI = 
mode of inheritance; PME = progressive myoclonic epilepsy; RRF = ragged red fibers
1. Muona et al [2015]
2. Action myoclonus - renal failure syndrome typically comprises a continuum of two major (and ultimately fatal) manifestations: 
progressive myoclonic epilepsy and renal failure; however, in some instances, the kidneys are not involved. Neurologic manifestations 
can appear before, simultaneously, or after the renal manifestations.
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with progressive myoclonic epilepsy type 
1 (EPM1), the evaluations summarized in Table 3 (if not performed as part of the evaluation that led to the 
diagnosis) are recommended.
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Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with EPM1
System/Concern Evaluation Comment
Neurologic
Neurologic assessment of myoclonus, incl myoclonus 
at rest, w/action, & in response to stimuli Use standardized UMRS.
Seizure type & frequency Obtain baseline EEG before initiation of antiseizure therapy (when EEG is most characteristic).
Cerebellar motor dysfunction (gait & postural ataxia, 
dysmetria, dysdiadochokinesis, tremor, dysarthria, 
nystagmus, saccades & smooth pursuit)
Use standardized scale to establish baseline for ataxia 




By physical medicine & rehabilitation/OT/PT
To assess gross motor & fine motor skills, gait, 
ambulation, need for adaptive devices, need for ongoing 
PT/OT
Speech For those w/dysarthria: speech & language eval Consider referral to speech & language pathologist.
Cognitive Neuropsychologist Cognitive eval to establish baseline





• To incl motor, adaptive, cognitive, & speech/
language eval
• Evaluation for special education
Genetic
counseling By genetics professionals 
1
To inform affected individuals & their families about the 
nature, MOI, & implications of EPM1 to facilitate 




• Use of community or online resources such as 
Parent to Parent and patient organizations;
• Need for social work involvement for parental 
support;
• Need for home nursing referral.
To facilitate peer support for patients & families
BARS = Brief Ataxia Rating Scale; ICARS = International Cooperative Ataxia Rating Scale; MOI = mode of inheritance; OT = 
occupational therapist/therapy; PT = physical therapist/therapy; SARA = Scale for the Assessment and Rating of Ataxia; UMRS = 
Unified Myoclonus Rating Scale
1. Medical geneticist, certified genetic counselor, or certified advanced genetic nurse
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Treatment of Manifestations




Valproic acid First drug of choice; diminishes myoclonus & frequency of generalized seizures
Clonazepam FDA-approved for treatment of myoclonic seizures; used as add-on therapy 1
High-dose piracetam Useful in treatment of myoclonus 2
Levetiracetam, 
brivaracetam, 3 perampanel 4
Appears effective for both myoclonus & generalized 
seizures
Topiramate & zonisamide May be used as add-on therapies
N-acetylcysteine Variable results 5
Vagus nerve stimulation Reduces seizures & significantly improves cerebellar function on neurologic exam 6
Other Avoid extreme stimuli (lights, noises, stress).
Seizures Antiseizure medication
Activities of daily living PT/OT
• PT (balance exercises, gait training, muscle 
strengthening) to maintain mobility & 
function 1
• OT to optimize ADL (incl use of adaptive 
devices, e.g., weighted eating utensils & 
dressing hooks)
• Consider adaptive devices to maintain/
improve independence in mobility (e.g., canes, 
walkers, motorized chairs).
• Home adaptations to prevent falls (e.g., grab 
bars, raised toilet seats) & improve mobility 
(e.g., ramps to accommodate motorized 
chairs)
Developmental delay / Intellectual disability
See Developmental Delay / 
Intellectual Disability 
Management Issues.
Dysarthria Speech & language therapy Consider alternative communication methods as needed (e.g., writing pads & digital devices).
Dysphagia
Feeding therapy programs to 
improve nutrition & 
dysphagia & reduce 
aspiration risk
• Video esophagram may help define best food 
consistency.
• Education re strategies to mitigate aspiration
• PEG tube in advanced cases
Weight Nutrition assessment
• Consider nutritional & vitamin 
supplementation to meet dietary needs
• Avoid obesity, which can exacerbate 
difficulties w/ambulation & mobility
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Table 4. continued from previous page.
Manifestation/Concern Treatment Considerations/Other
Family support/resources Psychotherapy, peer support
ADL = activities of daily living; OT = occupational therapy; PEG = percutaneous endoscopic gastrostomy; PT = physical therapy
1. Shahwan et al [2005]
2. Koskiniemi et al [1998]
3. Kälviäinen et al [2016]
4. Crespel et al [2017]
5. Edwards et al [2002]
6. Smith et al [2000]
Developmental Delay / Intellectual Disability Management Issues
The following information represents typical management recommendations for school-age individuals with 
developmental delay / intellectual disability in the United States; standard recommendations may vary from 
country to country.
All ages. Consultation with a developmental pediatrician is recommended to ensure the involvement of 
appropriate community, state, and educational agencies (US) and to support parents in maximizing quality of 
life. Some issues to consider:
• Individualized education plan (IEP) services:
⚬ An IEP provides specially designed instruction and related services to children who qualify.
⚬ IEP services will be reviewed annually to determine whether any changes are needed.
⚬ As required by special education law, children should be in the least restrictive environment feasible 
at school and included in general education as much as possible and when appropriate.
⚬ PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's 
access to academic material. Beyond that, private supportive therapies based on the affected 
individual's needs may be considered. Specific recommendations regarding type of therapy can be 
made by a developmental pediatrician.
⚬ As a child enters the teen years, a transition plan should be discussed and incorporated in the IEP. 
For those receiving IEP services, the public school district is required to provide services until age 
21.
• A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be 
considered for those who require accommodations or modifications such as front-of-class seating, 
assistive technology devices, classroom scribes, extra time between classes, modified assignments, and 
enlarged text.
• Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a US public 
agency that provides services and support to qualified individuals. Eligibility differs by state but is typically 
determined by diagnosis and/or associated cognitive/adaptive disabilities.
• Families with limited income and resources may also qualify for supplemental security income (SSI) for 
their child with a disability.
Surveillance
Table 5. Recommended Surveillance for Individuals with EPM1
System/Concern Evaluation Frequency
Myoclonus Severity of myoclonus using UMRS
At least annually
Seizures Seizure type & frequency
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Table 5. continued from previous page.
System/Concern Evaluation Frequency
Cerebellar involvement Clinical eval
Per symptom progressionDysarthria Need for alternative communication method or speech therapy
Dysphagia Assess aspiration risk & feeding methods
Weight / Nutritional status
• Monitor BMI.
• Consult a nutritionist.
• High-calorie supplementation





Evaluate mood, signs of psychosis, & cognitive complaints to 
identify need for pharmacologic & psychotherapeutic 
interventions.
Per symptom progression & 
development of psychiatric symptoms
Family support/resources Interview Annually
BMI = body mass index; UMRS = Unified Myoclonus Rating Scale
Agents/Circumstances to Avoid
Phenytoin should be avoided, as it has been found to have aggravating side effects on the associated neurologic 
symptoms, and may even accelerate cerebellar degeneration [Eldridge et al 1983].
Sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin) and GABAergic drugs (tiagabine, 
vigabatrin) as well as gabapentin and pregabalin should in general be avoided as they may aggravate myoclonus 
and myoclonic seizures [Medina et al 2005].
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on 
clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this 
disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of 
inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The 
following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic 
status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to 
substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
Progressive myoclonic epilepsy type 1 (EPM1) is inherited in an autosomal recessive manner.
Risk to Family Members
Parents of a proband
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• The parents of an affected child are obligate heterozygotes (i.e., presumed to be carriers of one CSTB 
pathogenic variant based on family history).
• Molecular genetic testing is recommended for the parents of a proband to confirm that each parent is 
heterozygous for a CSTB pathogenic variant and allow reliable recurrence risk assessment. (De novo 
variants are known to occur at a low but appreciable rate in autosomal recessive disorders [Jónsson et al 
2017].)
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Sibs of a proband
• If each parent is known to be heterozygous for a CSTB pathogenic variant, each sib of an affected 
individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic 
carrier, and a 25% chance of being unaffected and not a carrier.
• A sib who inherits biallelic CSTB pathogenic variants is likely to have clinical manifestations similar to 
those of the proband; however, intrafamilial clinical variability may be observed (particularly if affected 
family members have compound heterozygous CSTB pathogenic variants; see Genotype-Phenotype 
Correlations).
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Offspring of a proband
• Unless an individual with EPM1 has children with an affected individual or a carrier, his/her offspring will 
be obligate heterozygotes (carriers) for a pathogenic variant in CSTB.
• Because of the low carrier rate in the general population, the risk that an affected individual would have 
children with a carrier is extremely low except in certain populations (see Prevalence).
Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a CSTB 
pathogenic variant.
Carrier Detection
Carrier testing for at-risk relatives requires prior identification of the CSTB pathogenic variants in the family.
Carrier testing for the reproductive partners of a known carrier is possible. Primarily, targeted testing for the 
dodecamer repeat expansion should be done, and if it remains negative, sequencing of CSTB should be 
considered.
Related Genetic Counseling Issues
Family planning
• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the 
availability of prenatal testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Testing
Once both CSTB pathogenic variants have been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic testing for EPM1 are possible.
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Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion 
of these issues may be helpful.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
• National Library of Medicine Genetics Home Reference
Unverricht-Lundborg disease
• American Epilepsy Society (AES)
www.aesnet.org
• EpiCARE: a European Reference Network for rare and complex epilepsies
www.epi-care.eu
• Epilepsy Foundation







Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. Progressive Myoclonic Epilepsy Type 1: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific 
Databases
HGMD ClinVar
CSTB 21q22.3 Cystatin-B CSTB database CSTB CSTB
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for Progressive Myoclonic Epilepsy Type 1 (View All in OMIM)
254800 MYOCLONIC EPILEPSY OF UNVERRICHT AND LUNDBORG
601145 CYSTATIN B; CSTB
Molecular Pathogenesis
CSTB encodes cystatin B, an inhibitor of several papain-family cysteine proteases, cathepsins. Cystatin B 
interacts with histones and cathepsin L in the nucleus where it could regulate cathepsin L activity [Ceru et al 
2010].
Cstb-deficient knockout mice display a phenotype similar to the human disease with progressive ataxia and 
myoclonic seizures [Pennacchio et al 1998]. The mice show early microglial activation and inflammation, 
preceding clinical onset of myoclonus [Tegelberg et al 2012, Okuneva et al 2015, Okuneva et al 2016]. In 
Progressive Myoclonic Epilepsy Type 1 11
addition, altered GABAergic signaling with subsequent loss of GABA inhibition have been reported in Cstb-
deficient knockout mice, suggesting a mechanism for latent hyperexcitability resulting in myoclonus and 
seizures [Franceschetti et al 2007, Buzzi et al 2012, Joensuu et al 2014].
Impaired redox homeostasis has been reported as a pathophysiologic mechanism in Cstb-deficient knockout 
mice with cystatin-B-cathepsin B signaling dysregulation being a critical mechanism coupling oxidative stress to 
neuronal degeneration and death [Lehtinen et al 2009].
Mechanism of disease causation. Loss of function. Dodecamer repeat expansion results in a significantly 
reduced amount of CSTB mRNA: 5%-10% of the expression found in controls [Joensuu et al 2007]. Other 
disease-associated variants also result in loss of cystatin-B function and some are associated with total lack of 
intracellular cystatin B [Joensuu et al 2007, Joensuu et al 2008].
Table 6. CSTB Technical Considerations
Technical Issue Comment [Reference]
Sequence of repeat CCC-CGC-CCC-GCG
Methods to detect expanded 
allele (see Table 7)
Southern blotting [Lalioti et al 1997] & PCR for expanded repeat analysis [Joensuu et al 2007] have 
been described.
Somatic instability There is no evidence for substantial somatic instability of the expanded repeat.
Germline instability Expanded repeats show some instability in germline transmissions, w/both contractions & expansions implied. No tendency for expansion in successive generations has been reported.
Methods to characterize CSTB CCC-CGC-CCC-GCG repeats. Due to the technical challenges of detecting 
and sizing CSTB CCC-CGC-CCC-GCG repeat expansions, multiple methods may be needed to rule out or 
detect CCC-CGC-CCC-GCG repeat expansion (see Table 7). Repeats in the normal range (2-3) are detected by 
traditional PCR. However, detection of apparent homozygosity for a normal repeat by traditional PCR does not 
rule out the presence of an expanded repeat, thus, testing by a specific PCR method for expansion detection or 
Southern blotting is required.
Table 7. Methods to Characterize CSTB CCC-CGC-CCC-GCG Repeats
Interpretation of CCC-CGC-CCC-GCG 
Repeat Number
Expected Results by Method
Conventional PCR Expanded repeat analysis 1
Normal: 2-3 Detected 2 Expansions can be detected, & repeat size can 
be approximated 3, 4Pathogenic (full penetrance): ≥30 Not detected
1. Methods to detect and approximate the size of expanded repeats include long-range PCR sized by gel or capillary electrophoresis and 
Southern blotting. The upper limit of repeat size detected will vary by assay design, laboratory, sample, and/ or patient due to 
competition by the normal allele during amplification.
2. Detection of an apparently homozygous repeat does not rule out the presence of an expanded repeat; thus, testing by expanded 
repeat analysis is required to detect a repeat expansion.
3. Southern blotting [Lalioti et al 1997] and a specific PCR protocol [Joensuu et al 2007] for the CCC-CGC-CCC-GCG repeat 
expansion have been described
4. Precise sizing of repeats is not necessary as clinical utility for determining the exact repeat number has not been demonstrated.
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Table 8. Notable CSTB Pathogenic Variants
Reference Sequences DNA Nucleotide Change Predicted Protein Change Repeat Range
NM_000100.4
c.-179_-190CCCCGCCCCGCG[2_3] -- Normal variants
c.-179_-190CCCCGCCCCGCG[12_17] -- Uncertain significance
c.-179_-190CCCCGCCCCGCG[30_?] -- Full-penetrance
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of 
variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick 
Reference for an explanation of nomenclature.
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